On the Move | WRAL TechWire

On the Move

Ex-Research Triangle partnership COO Nance joins engineering/land planning firm Stewart

Lee Anne Nance, who left her job as chief operating officer at the research Triangle Regional Partnership to launch a consulting firm, is joining Raleigh-based Stewart as its chief strategic officer. Nance left the RTRP in July of 2016 in the midst of several management changes, including the retirement of long-time CEO Charles Hayes. Nance launched Britt Nance Collaborative and had worked with Stewart. “Through my economic development work as principal of Britt Nance Collaborative, I’ve had the chance to work extensively with Stewart,” Nance said. “Now as the company continues to grow, it’s a special opportunity to bring...

Read More

Former GSK CEO Witty joins Hatteras Venture Partners

Andrew Witty, who recently retired as CEO at drug giant GlaxoSmithKline, is now a partner at Hatteras Venture Partners. Hatteras announced Witty’s addition early Tuesday. “We are thrilled to welcome Andrew to Hatteras Venture Partners. He brings unparalleled strategic insights and extensive industry experience to the firm and to our portfolio of emerging companies,” said Bob Ingram, General Partner of Durham-based Hatteras. “Having had the pleasure of serving as Andrew’s mentor when I was CEO of Glaxo, it is hard to fully express my pride in having him join our dynamic team of company builders.” Witty has another Triangle...

Read More

RTP headlines: AT&T CEO’s new role; IBM downgraded; Pfizer exec to GSK; Red Hat cloud move; Lenovo channel changes

In WTW’s latest roundup of technology news impacting the Triangle: Report: AT&T CEO to become exec chair after Time Warner deal Read more at: https://www.reuters.com/article/time-warner-att-ma-idUSL4N1K5210 ​IBM Downgraded to Strong Sell: What’s Hurting the Stock? Read more at: http://www.nasdaq.com/article/ibm-downgraded-to-strong-sell-whats-hurting-the-stock-cm815912 ​Pfizer’s medicinal sciences head Tony Wood jumps ship to GSK Read more at: http://www.fiercebiotech.com/biotech/pfizer-s-medicinal-sciences-head-tony-wood-jumps-ship-to-gsk ​Red Hat shifts into overdrive with OpenShift Online cloud platform Read more at: Red Hat shifts into overdrive with OpenShift Online cloud platform Lenovo Changes Its North American Channel Focus Read more at:...

Read More

G1 Therapeutics names former GSK top exec Andrew Witty to board

Andrew Witty, formerly CEO of drug giant GlaxoSmithKline, is now a member of the board of directors at RTP-based G1 Therapeutics. The company, which is developing therapies to fight cancer, recently went public for more than $100 million. Two candidates are under clinical development. Witty retired from GSK earlier this year. He currently is chancellor of the University of Nottingham in England. “We are thrilled to welcome Andrew to our board of directors,” said Mark Velleca, G1 Therapeutics’s CEO, in the announcement, which was made Thursday. “Andrew led and oversaw the development, commercialization, and global market access for several...

Read More